{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.28","upperLimit":"11.99","value":"8.11"},{"groupId":"OG001","lowerLimit":"5.55","upperLimit":"11.79","value":"6.34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"To evaluate progression-free survival","dispersionType":"95% Confidence Interval","groups":[{"description":"Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.\n\nSVd (Selinexor+Bortezomib+dexamethasone): Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)","id":"OG000","title":"SVd (Selinexor+Bortezomib+Dexamethasone)"},{"description":"Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.\n\nVd (Bortezomib+dexamethasone): Vd Arm (\\~50): Bortezomib (Cycles 1-8 \\[BIW\\], Cycles ≥ 9 \\[QW\\]) + dexamethasone (Cycles 1-8 \\[Four times a week\\], Cycles ≥ 9 \\[BIW\\])","id":"OG001","title":"Vd (Bortezomib+Dexamethasone)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented PD (per IMWG criteria) or date of death, whichever occurs first. Participants without PD or death at the time of analysis are censored at the date of their last adequate disease assessment.","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"month"}